SOURCE: Actinium Pharmaceuticals

Actinium Pharmaceuticals

June 28, 2016 07:00 ET

Actinium Sponsored Acute Myeloid Leukemia (AML) Awareness Month to Feature Webinar Focused on Transplantation as a Treatment Option for Blood Cancers

NEW YORK, NY--(Marketwired - June 28, 2016) -

Webinar to be held on Tuesday, June 28, 2016 from 1:30 - 2:30 pm ET

John Pagel, M.D., Ph.D., Actinium Advisory Board Member, and Panel of Experts to Discuss Bone Marrow Transplant

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that a webinar focused on transplantation as a treatment option for blood cancers will be hosted by CancerCare® as part of their first AML Awareness Month, which is sponsored by Actinium.

Event: Transplantation as a Treatment Option for Blood Cancers
Date: Tuesday, June 28, 2016
Time: 1:30 - 2:30 PM Eastern Time
Link: http://www.cancercare.org/connect_workshops/538-transplantation_blood_cancer_treatment_option_2016-06-28

The webinar will address the following topics:

  • Overview & Types of Transplantation
  • Transplantation as a Treatment Option for:
    • Multiple Myeloma
    • Leukemia
    • Lymphoma
    • Myeloproliferative Neoplasms (MPN)
  • Guidelines for Transplantation
  • Searching for a Donor
  • Follow-Up Care
  • Practical Tips to Manage Post Treatment Concerns
  • Graft vs. Host Disease
  • Clinical Trials
  • Communicating with Your Health Care Team
  • Quality-of-Life Concerns
  • Questions for the Panel of Experts

Sandesh Seth, Actinium's Executive Chairman stated, "Actinium, through our Iomab-B program, is intensely focused on bone marrow transplants for AML, the deadliest type of blood cancer. We are delighted to see CancerCare driving awareness to this overlooked area of patient care with this educational webinar event and we are grateful for the opportunity to sponsor the first ever AML Awareness Month."

About Iomab-B

Iomab-B is about to begin the pivotal, Phase 3 SIERRA trial and is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct the single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information